Panacea Biotec Ltd. — Capital/Financing Update 2019

Apr 8, 2019

April 08, 2019

The Manager, Listing Department The National Stock Exchange oflndia Ltd. Exchange Plaza, Bandra Kurla Complex, Sandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 00 I BSE Scrip Code: 531349

Sub.: Intimation with respect to allotment of unrated, unlisted, unlisted, redeemable nonconvertible debentures

Re: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to our letter dated February 26, 2019 intimating that the Board of Directors had in its meeting held on that day, approved issuance of listed/unlisted, secured/unsecured redeemable Non-Convertible Debentures, on private placement basis upto Rs.864 Crore in one or more series/tranches.

We would now like to inform you that the Executive Committee of the Board of Directors of the Company had, in its meeting held on April 08, 2019, approved the allotment of 74,300 unrated, unlisted, redeemable, non-convertible debentures (NCDs), having the face value of Rs. 1,00,000/- (Rupees One Lakh Only) each, aggregating to Rs.743 Crore under Series lA, Series IB and Series 2 NCDs. The details of the said allotment are mentioned in Annexure-A.

This is for your kind information and record please.

Kindly acknowledge the receipt.

Thanking you,

Encl. As Above

B1 Extn. IG3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: 0.1.0. +91-11-4167 9015 Fax: +91-11-4167 9070

Panacea Biotec Ltd.

Annexure-A

S. No.	Particulars	Description
I.	Type of securitiesproposed to be issued	Non-ConvertibleDebentures
2.	Type of issuance	Private Placement
3.	Total number of securities proposed to beissued or the total amount for which thesecurities will be issued (approximately)	Private Placementby issuing74,300 (SeventyFourThousandThreeHundredOnly)unrated,unlisted,securedNon-ConvertibleDebentures("NCD")ofRs.l,OO,OOO each("DebenturesIssuePrice"),incompliancewith the provisionsof CompaniesAct,2013 and the rules made thereunder.
4.	Additionalinformationin case of issuanceof debt securities
I.	Size of the issue	Rs.743,00,00,000
ii.	Whetherproposedto be listed?lfyes,nameof the stock exchange(s);	The said NCDs are not proposed to be listed
III.	Tenureof the instrument(with date ofallotmentand date of maturity)	NCDSeries	Date ofAllotment	Date ofMaturity	[l'euure
I		1A	08.04.2019	08.04.2020	12 monthsand IBusinessDay
		IB	08.04.2019	07.04.2024	60 months
		2	08.04.2019	17.10.2020	18 months& 10 days
IV.	CouponRate / Scheduleof PaymentofCoupon/ interestand principal	20% IRR will be paid on the NCDs (Cash Coupon +RedemptionPremium)Scheduleof PrincipalPayment
		NCDSeries	Recorddate forTenurePrincipalPayment
		IA	12 months and 1Business Day		08.04.2020
		lB	60 months		07.04.2024
		2	18 months & 10 days		17.10.2020
v.	Charge/Security,if any created		The security package will include (among others):
	over the assets	i)Exclusivefirst charge on all fixed and currentassets,and pledgeon at least 64.94%of theequitysharecapitalof the Company(in twotranches,viz.51.04%upfrontand remaining13.90%postdemergerofRadhika"Limited)heldbyPromotersaqlji~~

I c:( <t-i \0 rot. ',0.",., •• "'CI.;.oJr'") '"-:~'7:R ...

		ii)iii)	Group.PersonalGuaranteesprovidedby Dr. RajeshJain, Mr. Sandeep Jain and Mr. Ankesh JainCorporateguaranteeprovidedbytheCompany'sWholly-ownedSubsidiaryPanacea Biotec Pharma Limited
VI.	Specialrights / interest/ privilegesattachedto the instrumentandchangesthereof;	NA
VII.	Delayin paymentof interest/ principalamountfor a periodof morethanthreemonthsfromtheduedateordefaultinpaymentof interest/ principal	NA
VIII.	Detailsofanyletterorcommentsregardingpayment/non-paymentofinterest,principalonduedates,oranyothermatterconcerningthe securityand/ ortheassetsalongwithits commentsthereon,if any	NA
IX.	Detailsofredemptionofpreferencesharesindicatingthemannerofredemption(whetherout of profitsor outof freshissue) and debentures	NA